245 related articles for article (PubMed ID: 36248960)
1. Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation.
Shen X; Wang X; Lu X; Zhao Y; Guan W
Front Oncol; 2022; 12():967071. PubMed ID: 36248960
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic alterations in pancreatic neuroendocrine tumors.
Tirosh A; Kebebew E
J Gastrointest Oncol; 2020 Jun; 11(3):567-577. PubMed ID: 32655936
[TBL] [Abstract][Full Text] [Related]
3. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.
Nuñez JE; Donadio M; Filho DR; Rego JF; Barros M; Formiga MN; Lopez R; Riechelmann R
J Gastrointest Oncol; 2019 Aug; 10(4):645-651. PubMed ID: 31392045
[TBL] [Abstract][Full Text] [Related]
5. Genetics of Pancreatic Neuroendocrine Tumors.
Mohindroo C; McAllister F; De Jesus-Acosta A
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1033-1051. PubMed ID: 36154786
[TBL] [Abstract][Full Text] [Related]
6. The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.
Pipinikas CP; Berner AM; Sposito T; Thirlwell C
Endocr Relat Cancer; 2019 Aug; 26(9):R519-R544. PubMed ID: 31252410
[TBL] [Abstract][Full Text] [Related]
7. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
Scarpa A
Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.
Wong HL; Yang KC; Shen Y; Zhao EY; Loree JM; Kennecke HF; Kalloger SE; Karasinska JM; Lim HJ; Mungall AJ; Feng X; Davies JM; Schrader K; Zhou C; Karsan A; Jones SJM; Laskin J; Marra MA; Schaeffer DF; Gorski SM; Renouf DJ
Cold Spring Harb Mol Case Stud; 2018 Feb; 4(1):. PubMed ID: 29092957
[TBL] [Abstract][Full Text] [Related]
9. Management of functional neuroendocrine tumors of the pancreas.
Öberg K
Gland Surg; 2018 Feb; 7(1):20-27. PubMed ID: 29629316
[TBL] [Abstract][Full Text] [Related]
10. Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors.
Buicko JL; Finnerty BM; Zhang T; Kim BJ; Fahey TJ; Nancy Du YC
Ann Pancreat Cancer; 2019 Jun; 2():. PubMed ID: 31535089
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
[TBL] [Abstract][Full Text] [Related]
12. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
Maxwell JE; Sherman SK; Howe JR
Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic Neuroendocrine Tumors: an Update.
Paniccia A; Edil BH; Schulick RD
Indian J Surg; 2015 Oct; 77(5):395-402. PubMed ID: 26722203
[TBL] [Abstract][Full Text] [Related]
14. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.
Vandamme T; Beyens M; Boons G; Schepers A; Kamp K; Biermann K; Pauwels P; De Herder WW; Hofland LJ; Peeters M; Van Camp G; Op de Beeck K
Endocr Relat Cancer; 2019 Jan; 26(1):1-12. PubMed ID: 30021865
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging therapies for PNETs in patients with or without MEN1.
Frost M; Lines KE; Thakker RV
Nat Rev Endocrinol; 2018 Apr; 14(4):216-227. PubMed ID: 29449689
[TBL] [Abstract][Full Text] [Related]
16. Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical Workup.
Ciobanu OA; Martin SC; Herlea V; Fica S
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139607
[TBL] [Abstract][Full Text] [Related]
17. Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
Gleeson FC; Voss JS; Kipp BR; Kerr SE; Van Arnam JS; Mills JR; Marcou CA; Schneider AR; Tu ZJ; Henry MR; Levy MJ
Oncotarget; 2017 Nov; 8(55):93464-93475. PubMed ID: 29212165
[TBL] [Abstract][Full Text] [Related]
18. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
[TBL] [Abstract][Full Text] [Related]
19. Animal models of spontaneous pancreatic neuroendocrine tumors.
Yu R
Mol Cell Endocrinol; 2016 Feb; 421():60-7. PubMed ID: 26261055
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic neuroendocrine tumors: Nosography, management and treatment.
Orditura M; Petrillo A; Ventriglia J; Diana A; Laterza MM; Fabozzi A; Savastano B; Franzese E; Conzo G; Santini L; Ciardiello F; De Vita F
Int J Surg; 2016 Apr; 28 Suppl 1():S156-62. PubMed ID: 26708853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
